Cancer as an infectious disease: A different treatment alternative using a combination of tigecycline and pyrvinium pamoate - An example of breast cancer
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Journal Volume
55
Journal Issue
1
Pages
51
Date Issued
2022-02
Author(s)
Huang, Shu-Wei
Sun, Ming-Tsung
Lee, Wen-Sen
Su, Ying-Shih
Lee, Yi-Tzu
Chiang, Ming-Hsien
Wang, Yung-Chih
Yang, Ya-Sung
Tzeng, Shian-Chiuan
Wu, Tien-Yuan
Sun, Jui-Sheng
Abstract
Tigecycline is an antibiotic that well tolerated for treating complicated infections. It has received attention as an anti-cancer agent and expected to solve two major obstacles, sides effects that accompany chemotherapy and drug resistance, in the breast cancer treatment. However, previous studies reported that the levels in the blood are typically low of tigecycline, so higher doses are needed to treat cancer, that may increase the risk of side effects. To achieve better anti-cancer effects for tigecycline, we need to find a novel adjunct agent.
Subjects
Breast cancer; Combination therapy; Pyrvinium pamoate; Tigecycline
Publisher
ELSEVIER TAIWAN
Type
journal article